Contact Us
Drug Search Results
More Filters [+]

Tazemetostat

Alternative Names: tazemetostat, epz-6438, epz6438, tazverik
Latest Update: 2024-12-12
Latest Update Note: Clinical Trial Update

Product Description

a first-in-class, oral EZH2 inhibitor for patients with follicular lymphoma. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33035457/)

Mechanisms of Action: EZH2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Accelerated Approval - Follicular Lymphoma|Lymphoma
Accelerated Approval - Sarcoma
Priority Review - Follicular Lymphoma|Lymphoma *

Approval Status: Approved

Approved Countries: Czech | Japan | United States

Approved Indications: Sarcoma

Known Adverse Events: Pain Unspecified | Constipation

Company: Epizyme
Company Location: CAMBRIDGE MA 02139
Company CEO: Grant Bogle
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tazemetostat

Countries in Clinic: Australia, Belgium, Canada, China, France, Germany, Hungary, Italy, Korea, Poland, Slovakia, Spain, Taiwan, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 28

Highest Development Phases

Phase 3: Follicular Lymphoma|Sarcoma

Phase 2: Breast Cancer|Burkitt Lymphoma|Cholangiocarcinoma|Chordoma|Clear Cell Adenocarcinoma|Clear Cell Sarcoma|Colorectal Cancer|Diffuse Large B-Cell Lymphoma|Ductal Breast Carcinoma|Ductal Carcinoma|Endometrial Cancer|Endometrioid Carcinoma|Enteropathy-Associated T-Cell Lymphoma|Esophageal Cancer|Gastrointestinal Cancer|Hepatocellular Carcinoma|Immunoblastic Lymphadenopathy|Intestinal Diseases|Large Cell Carcinoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Medullary Carcinoma|Mesothelioma|Neurofibrosarcoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Peritoneal Cancer|Prostate Cancer|Relapsed/Refractory Lymphoma|Renal Cell Carcinoma|Rhabdoid Tumor|Small Cell Lung Cancer|Synovial Sarcoma|T-Cell Peripheral Lymphoma|Transitional Cell Carcinoma|Uterine Cancer|Waldenstrom Macroglobulinemia

Phase 1: Liver Cancer|Mantle-Cell Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT05994235

P2

Recruiting

Follicular Lymphoma

2033-10-01

2019-003648-55

P3

Unknown status

Sarcoma

2029-08-17

Mandolin

P2

Not yet recruiting

Follicular Lymphoma

2029-04-06

EZH-302

P3

Unknown Status

Follicular Lymphoma

2029-03-01

Recent News Events

Date

Type

Title

09/26/2024

News Article

 NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer

08/06/2024

News Article

 Sarcoma Therapeutics Market size is set to grow by USD 1.11 billion from 2024-2028, Patient assistance programs boost the market, Technavio

07/29/2024

News Article

 Myrobalan Therapeutics Names Grant Bogle to Board of Directors

05/23/2024

News Article

 Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions